# A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

> **NCT00108953** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 96 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- **DRUG:** Doxorubicin/Placebo

## Key facts

- **NCT ID:** NCT00108953
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2014-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00108953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00108953, "A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00108953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*